14 results about "Quinolinic acid" patented technology

Provided herein is the use of certain biomarkers, such as tryptophan and metabolites thereof for use in certain treatment methods. Suitable tryptophan metabolites that may serve as useful biomarkers include, for example, kynurenine (Kyn), kynurenic acid (KynA), and quinolinic acid. Such biomarkers may be used in identifying a subject who may benefit from treatment, predicting the responsiveness or monitoring the response of the subject to the treatment, or determining or adjusting the dosing or dosing regimen of the treatment to the subject.

The invention discloses a quinolinic acid diaryl ether derivative, a preparation method and application thereof and a bacteriostatic agent or bactericide, relates to the technical field of medicinal chemistry, solves the problems that existing pesticides are high in toxicity and not environmentally friendly, easily cause drug resistance of pathogenic bacteria and possibly have negative effects on the environment and an ecological system, can efficiently prevent and treat fungal diseases of plants, and also can effectively prevent and treat the pathogenic bacteria of the plants. The quinolinic acid diarylether derivative has the advantages that the quinolinic acid diarylether derivative has excellent inhibition activity on agricultural fungi such as rhizoctonia solani, sclerotinia sclerotiorum, botrytis cinerea, fusarium graminearum and fusarium pseudograminearum, and the quinolinic acid diarylether derivative has the characteristics of simple synthesis process, cheap and easily available raw materials, good control effect, wide bactericidal spectrum and the like.

The application relates to a reagent combination for detecting depression, a manufacturing method, a detection system and application thereof, and belongs to the technical field of instrument detection. The reagent combination for detecting depression comprises a calibrator, a quality control sample and an extraction solution of a to-be-detected compound serving as a biomarker; wherein the to-be-detected compound is at least three kinds selected from 5-hydroxyanthranilic acid, methionine, gamma-aminobutyric acid, 3,4-dihydroxyphenylacetic acid, 2-picolinic acid, quinolinic acid, kynurenine, 5-hydroxytryptamine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, dopamine and norepinephrine. The reagent combination for detecting depression and the detection system can significantly improve the accuracy of diagnosis, are convenient to detect, have good repeatability of detection data, are high in specificity, and are accurate in clinical diagnosis results.

The mass ratio of quinolinic acid to clindamycin is (1-3): (7-9), after the clindamycin and the quinolinic acid are used in a combined mode, a synergistic effect is achieved in the aspect of prevention and treatment of the Chinese cabbage soft rot, and compared with the concentration required for bacteriostasis of single clindamycin or single quinolinic acid, the concentration required for bacteriostasis of the clindamycin and the quinolinic acid is reduced, so that the effect of preventing and treating the Chinese cabbage soft rot is improved. After compounding, the use amount of the two is greatly reduced, and the composition has a remarkable control effect on the soft rot of the Chinese cabbage.

This invention discloses the application of quinolinic acid in the preparation of drugs for the prevention and treatment of acute kidney injury (AKI). AKI refers to acute kidney injury induced by renal ischemia-reperfusion. The drug is an oral formulation used for prophylactic administration in high-risk individuals undergoing iatrogenic procedures at potential AKI risk, and for pretreatment of ischemic conditions in transplanted kidneys. Experiments have shown that administration of quinolinic acid significantly reduces serum urea nitrogen levels in AKI mice, alleviates renal tissue morphological damage in AKI mice, and reduces the expression level of the renal tubular injury factor NGAL protein in AKI mice, demonstrating significant clinical value in the prevention and treatment of AKI.

The invention discloses a succinate dehydrogenase mutant and application thereof, and belongs to the technical field of gene engineering. The succinate dehydrogenase mutant is obtained by mutation on the basis of an amino acid sequence as shown in SEQ ID NO.1, and the mutation site of the succinate dehydrogenase mutant is selected from at least one of the 117th site, the 119th site, the 134 site, the 256th site and the 402th site. The mutant has L-aspartic acid oxidase activity and shows high catalytic activity and specificity on aspartic acid when being applied to production of quinolinic acid, the catalytic efficiency of the mutant is superior to that of natural L-aspartic acid oxidase, and meanwhile, the substrate inhibition effect of the natural L-aspartic acid oxidase can be avoided; and the high activity can still be maintained under the high NAD < + > concentration. Therefore, by utilizing the mutant and the quinolinic acid synthesis method, the synthesis efficiency of the quinolinic acid can be remarkably improved, and the mutant and the quinolinic acid synthesis method have a good industrial application prospect.

The invention discloses preparation of functional sprouting vegetables and application of the functional sprouting vegetables in low-GI-value rice, and relates to the field of development of new application of food raw materials. Through analysis of sunflower seeds and sunflower bud seedlings germinating for 0-7 days, the polyphenol substance content of the bud seedlings is obviously increased. The sunflower bud seedling freeze-dried powder and the rice are cooked together, so that the starch structure of the rice can be regulated and controlled, and the content of resistant starch is increased. The hydrothermal treatment can promote the combination of characteristic polyphenol compounds chlorogenic acid (CHA) and 3, 5-di-O-caffeoylquinic acid (CQA) in sunflower bud seedlings and rice starch. Wherein the action effect of CQA is better than that of CHA; the CQA can effectively reduce the generation of rapidly digested starch and promote the formation of resistant starch through a dual mechanism of inhibiting the activity of digestive enzymes and forming a non-covalent complex with starch, so that the digestion process of the starch is delayed, and postprandial blood sugar response is reduced.

There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACTI peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof).

The invention belongs to the field of liver cirrhosis and hepatocellular carcinoma marker detection, and particularly relates to application of a metabolic marker detection reagent in preparation of liver disease diagnosis products. The metabolic marker is a combination of Nicotinamide N-oxide, Pregnandiol 3-O-glucose, Guanidoacetic acid, Glycine, Isomaltose, Picolinic acid, 2-Hydroxycyanic acid, Quinolinic acid, Carnosine, 3-Methyluridine, 3-Methyluridine and Formiminoglumic acid, and the metabolic marker is a combination of the Nicotinamide N-oxide, the Pregnandiol 3-O-glucose acid, the Guanidoacetic acid, the Glycine, the Isomaltose, the Picolinic acid, the 2-Hydroxycyanic acid, the Quinolinic acid, the Carnosine, the 3-Methyluridine, the 3-Methyluridine and the Formiminoglumic acid. The liver disease is liver cirrhosis or hepatocellular carcinoma. The 12 urine metabolism markers are combined to accurately distinguish normal people from patients with liver cirrhosis, and normal people from patients with hepatocellular carcinoma. The kit provides a brand-new and objective biological basis for early diagnosis, treatment and prognosis evaluation of liver cirrhosis and hepatocellular carcinoma.

The invention discloses a pyridine-2-carboxylic acid decarboxylase mutant and application of the pyridine-2-carboxylic acid decarboxylase mutant in production of nicotinic acid, and belongs to the technical field of genetic engineering. The pyridine-2-carboxylic acid decarboxylase mutant disclosed by the invention is obtained by mutation on the basis of an amino acid sequence as shown in SEQ ID NO.1, and the mutation sites of the mutant comprise the 26th site, the 68th site and the 184th site. A substrate quinolinic acid can be converted into nicotinic acid in one step by utilizing the mutant, compared with a chemical synthesis method, the synthesis method disclosed by the invention does not need to be carried out under high-temperature and high-pressure conditions, and sulfuric acid or hydrochloric acid does not need to be additionally added, so that possible environmental hazards are reduced; meanwhile, the method is simple in process, high in conversion rate and stable in effect, and has a good industrial application prospect.

A kind of algorithm model for depression detection, detection system, program and storage medium.The training method of the artificial intelligence model includes: constructing artificial intelligence model, its input includes the concentration of 3-4 kinds of to-be-detected compounds selected from 5-hydroxyanthranilic acid, methionine, gamma-aminobutyric acid, 3,4-dihydroxyphenylacetic acid, 2-picolinic acid, quinolinic acid, kynurenine, 5-hydroxytryptamine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, dopamine, norepinephrine, homocysteine, and the output is the risk index of suffering from severe depression;Large sample data is used to train the artificial intelligence model.The AUC of the detection model of the application is greater than or equal to 0.95, even 0.99;Accuracy rate reaches more than 90%;High sensitivity;Algorithm is simple, iterative convergence is fast, is convenient for transplantation, can be embedded into detection system, also can be used as a single data processing unit, works using encryption key or external U disk mode.

[Problem] To suggest the possibility of olfactory / gustatory abnormality (impairment) by means of a numerical value based on the metabolism of tryptophan in the kynurenine pathway. [Solution] A system 1 for evaluating a person suffering from COVID-19 comprises: an acquisition means 10 for acquiring a numerical value based on the metabolism of tryptophan in the kynurenine pathway obtained by analyzing serum S during an acute phase of COVID-19 in a person suffering from COVID-19; and an evaluation means 30 that indicates the possibility of olfactory / gustatory abnormality (impairment) in the person suffering from COVID-19 on the basis of the numerical value (for example, a KTR value or a blood concentration value for quinolinic acid).

The invention relates to the technical field of medical kits, and provides a potential serum marker for diagnosing inhalation pneumonia, the biomarker is selected from six kinds of materials including quinolinic acid, phosphatidylcholine (18: 0 / 20: 4 (5Z, 8Z, 11Z, 14Z)), N6, N6, N6-trimethyl-L-lysine, lysophosphatidylcholine (17: 0 / 0: 0), DL-piperidine acid and galactitol. The kit comprises a calibration product, a low-value quality control product, a high-value quality control product, an internal standard product, a protein precipitant, a diluent, an electrolyte concentrated solution I and an electrolyte concentrated solution II, the six biomarkers can accurately identify the inhaled pneumonia and the non-inhaled pneumonia, and the kit is developed around the six biomarkers. The method can well identify inhalation pneumonia and non-inhalation pneumonia, and solves the technical problem of missed diagnosis of patients with early-stage inhalation pneumonia.

The application discloses a synthesis method of quinolinic acid, which comprises the following steps: (1) using a halogenated pyridine derivative as raw material, performing a Grignard reaction with a Grignard reagent solution to generate a first intermediate; (2) performing a carbonylation reaction on the first intermediate with carbon dioxide to obtain a second intermediate; and (3) performing an oxidation reaction on the second intermediate with an oxidizing agent to obtain a product quinolinic acid, and the specific reaction is shown in the following formula, wherein X is halogen, R is C 1‑3 alkyl or cyano, and R1 is C 2‑4 alkyl. The application provides a new method for preparing 2,3-pyridinedicarboxylic acid (quinolinic acid), which uses a halogenated and alkyl-substituted or cyano-substituted pyridine derivative as raw material, performs a Grignard reaction with a Grignard reagent, then performs a carbonylation reaction with carbon dioxide, and finally performs hydrolysis to obtain the product 2,3-pyridinedicarboxylic acid (quinolinic acid). The synthesis route has the advantages of mild reaction, easy operation, safety and environmental protection, and convenience for large-scale production.